Shots:

• Eli Lilly and Incyte report the initial result of NIAID sponsored ACTT-2 study assessing the efficacy and safety of Olumiant (baricitinib- 4mg) + Veklury (remdesivir) vs Veklury as monothx. in hospitalized patients with COVID-19
• The study met its EPs i.e. it demonstrated 1day reduction in median recovery time for the overall patient population and met its 2EPs i.e. comparing patient outcomes at Day 15 using an ordinal 8-point scale ranging from fully recovered to death
• Lilly plans to discuss the potential of baricitinib for the US FDA’s EUA and to explore similar measures with other regulatory bodies. Additionally- Lilly will review the ACTT-2 data with NIAID and assess any impact on P-III COV-BARRIER study- initiated in June to assess baricitinib vs background therapy in hospitalized adults with COVID-19 in the US- EU- Asia- and Latin America

­ Ref: PRNewswire | Image: Eli Lilly